AstraZeneca Pharma India Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Sanjeev Panchal
Chief executive officer
₹38.7m
Total compensation
| CEO salary percentage | 83.4% |
| CEO tenure | 2yrs |
| CEO ownership | n/a |
| Management average tenure | 1.5yrs |
| Board average tenure | 1yrs |
Recent management updates
Recent updates
Investors Appear Satisfied With AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Prospects
Dec 31
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors
Sep 18We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹819m |
| Jun 30 2024 | n/a | n/a | ₹959m |
| Mar 31 2024 | ₹39m | ₹32m | ₹2b |
| Dec 31 2023 | n/a | n/a | ₹1b |
| Sep 30 2023 | n/a | n/a | ₹2b |
| Jun 30 2023 | n/a | n/a | ₹1b |
| Mar 31 2023 | ₹21m | ₹5m | ₹993m |
Compensation vs Market: Sanjeev's total compensation ($USD451.15K) is about average for companies of similar size in the Indian market ($USD488.47K).
Compensation vs Earnings: Sanjeev's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Sanjeev Panchal (47 yo)
2yrs
Tenure
₹38,725,314
Compensation
Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, Country President & Director | 2yrs | ₹38.73m | no data | |
| Whole-Time Director & CFO | 1.3yrs | ₹30.59m | no data | |
| Legal Counsel | 7.9yrs | ₹3.73m | no data | |
| Company Secretary & Compliance Officer | 2.4yrs | no data | no data | |
| Vice President of Human Resources | no data | ₹12.28m | no data | |
| Interim Business Unit Head of Oncology & Director of Commercial Excellence | 1.5yrs | no data | no data | |
| Head of Oncology Business Unit | 1.2yrs | no data | no data | |
| Business Unit Head - Rare Disease unit | less than a year | no data | no data | |
| Legal Head | no data | no data | no data |
1.5yrs
Average Tenure
Experienced Management: ASTRAZEN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, Country President & Director | 2yrs | ₹38.73m | no data | |
| Whole-Time Director & CFO | less than a year | ₹30.59m | no data | |
| Independent Non-Executive Director | 8.1yrs | ₹1.20m | no data | |
| Additional Independent Director | less than a year | no data | no data | |
| Additional Non-Executive Director | 1.2yrs | no data | no data | |
| Independent Non-Executive Chairperson of the Board | 3.1yrs | ₹1.30m | no data | |
| Non-Executive Director | less than a year | no data | no data | |
| Additional Non-Executive Director | less than a year | no data | no data |
1.0yrs
Average Tenure
58yo
Average Age
Experienced Board: ASTRAZEN's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 15:51 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AstraZeneca Pharma India Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |